Arrowhead Pharmaceuticals (ARWR)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
At a market value of $8.6B, Arrowhead Pharmaceuticals's free cash flow of $157M (fiscal 2025) would need to grow about 18% a year for the stock to be worth today's price. That is faster than the company has grown its free cash flow over the last 6 years.
Assumes a 9% discount rate and 3% growth after year 10, on free cash flow (operating cash flow minus capital spending) from Arrowhead Pharmaceuticals's SEC filings. Change any assumption, or model revenue and margins instead, in the Modeling tab, or try your own numbers in the reverse DCF calculator.
Fundamental grade
Five factors scored 1 to 9 from ARWR's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from Arrowhead Pharmaceuticals's 10-K filings. The deep dive has 15+ years, quarters and every line.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $138M | $243M | $241M | $4M | $829M |
| Net income | -$141M | -$176M | -$205M | -$599M | -$2M |
| Free cash flow | $148M | -$189M | -$331M | -$604M | $157M |
| EPS (diluted) | -$1.36 | -$1.67 | -$1.92 | -$5.00 | -$0.01 |
| Operating margin | -107.8% | -73.4% | -85.2% | -16927.1% | 11.9% |
Superinvestors who own ARWR
From each investor's latest 13F filing (what a 13F shows). 3 of the investors we track hold it.
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| Cliff Asness AQR Capital Management |
Added | $16M | 0.01% | Q2 2026 |
| Hersh Cohen ClearBridge Investments |
Trimmed | $13M | 0.01% | Q2 2026 |
| Joel Greenblatt Gotham Asset Management |
Trimmed | $545,791 | 0.00% | Q2 2026 |
Insider buying
Open-market purchases by Arrowhead Pharmaceuticals's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when ARWR trades at or below it.
Free accounts get 3 price alerts. No card needed.
In the full deep dive
Questions
What growth does Arrowhead Pharmaceuticals's stock price imply?
At a market value of $8.6B, Arrowhead Pharmaceuticals would need its free cash flow to grow about 18% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price. Over the last 6 years its free cash flow grew -0% a year.
Are Arrowhead Pharmaceuticals insiders buying the stock?
No open-market insider purchases of ARWR in the last 12 months, according to SEC Form 4 filings.
Which superinvestors own Arrowhead Pharmaceuticals?
3 of the superinvestors Investingly tracks hold ARWR in their latest 13F, including Cliff Asness, Hersh Cohen, Joel Greenblatt.
Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.